PART 1: Performance Analysis

Aadi Bioscience, Inc. performed well during the period, reporting net revenue from product sales of $15.2 million for the fiscal year ended December 31, 2022. This revenue is due to FDA approval of FYARRO sirolimus protein-bound particles, a form of sirolimus bound to albumin, for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (“PEComa”). The company launched FYARRO in the United States on February 22, 2022, for the treatment of advanced malignant PEComa. Additionally, the company recorded $72.2 million in net proceeds from its 2022 private placement (PIPE) financing, which will fund working capital and other general corporate purposes.

Aadi Bioscience, Inc. has also shown a strong focus on future growth with the initiation of registration-directed tumor-agnostic Phase 2 study (“PRECISION 1”) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (“ TSC1 & TSC2 ”) alterations. The company has completed a Type B meeting with the FDA and began enrollment in the United States during the first quarter of 2022, with preliminary data expected during the second quarter of 2023. The company has also entered into a collaboration and supply agreement with Mirati Therapeutics, Inc. to evaluate the combination of adagrasib and FYARRO in KRAS G12C mutant non-small cell lung cancer (NSCLC) and other solid tumors.

PART 2: Forward-Looking Analysis

Aadi Bioscience, Inc. is well positioned for future success with its focus on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. The expedited FDA approval of FYARRO for the treatment of advanced malignant PEComa demonstrates the potential of the albumin-bound sirolimus approach to produce transformational therapies to cancer patients with mTOR pathway driver alterations. The company's collaboration with Mirati Therapeutics, Inc. to evaluate the combination of adagrasib and FYARRO in KRAS G12C mutant non-small cell lung cancer and other solid tumors further expands the potential applications of the products.

The successful completion of the PRECISION 1 trial and the expansion into new target populations could provide a significant boost to the company's revenue stream in the future. Moreover, the net proceeds from the recently completed PIPE financing will provide the company with funds to support its research and development activities.

However, the success of Aadi Bioscience, Inc. is predicated on the continued success of its product, FYARRO, which is still in early stages. The competitive landscape of the cancer treatment industry and the regulatory environment could also impact the company's future success. Therefore, investors should carefully consider the risks associated with investing in Aadi Bioscience, Inc. before making any decisions.

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

EX-10.4 - AMENDED AND RESTATED EXECUTIVE AGREEMENT, NEIL DESAI

EX-15.15 - BRE SUNSET COAST LLC, OFFICE LEASE

Aadi Bioscience Inc

Aadi Bioscience reports strong revenue in FDA-approved cancer drug FYARRO with strong growth potential.

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

Form 8-K/A - Current report: [Amend] - Item 5.02

Announcement: AADI 8-K/A Special Filing Amendment

Aadi Bioscience, a precision therapy-focused biopharmaceutical firm, has shared its financial results for 2022, with $15.2 million in sales being reported for the 10-month period. Additionally, the company's cash reserves will last until 2025. In terms of research and development, Aadi's collaboration with Mirati Therapeutics will be commencing in Q2 2023, and the results of their PRECISION 1 trial will be shared around the same time. The trial's independent TSC1 and TSC2 patient groups are both comprised of 60 individuals. Dr. Mohammad Hirmand has also been announced as a new member of the Board of Directors. CEO Scott Giacobello is optimistic about the company's progress, and Aadi Bioscience appears to have a bright road ahead.

Form 8-K - Current report - Item 2.02 Item 5.02 Item 9.01

$AADI reports $15.2M sales & strong cash reserves, sets new R&D collaboration & welcomes new board member

Form 8-K - Current report - Item 5.02 Item 7.01 Item 9.01

Announcement: AADI 8-K Special Filing

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Aadi Bioscience reports strong revenue in FDA-approved cancer drug FYARRO with strong growth potential.

Aadi Bioscience reports strong revenue in FDA-approved cancer drug FYARRO with strong growth potential.

Announcement: AADI 8-K/A Special Filing Amendment

Announcement: AADI 8-K/A Special Filing Amendment

$AADI reports $15.2M sales & strong cash reserves, sets new R&D collaboration & welcomes new board member

$AADI reports $15.2M sales & strong cash reserves, sets new R&D collaboration & welcomes new board member

Announcement: AADI 8-K Special Filing

Announcement: AADI 8-K Special Filing

Announcement: AADI SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: AADI SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: AADI SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: AADI SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment